CleftGeneDB-Search

Gene: E2F1

Basic information

Tag	Content
Uniprot ID	Q01094; Q13143; Q92768;
Entrez ID	1869
Genbank protein ID	AAA35782.1; AAM47604.1; AAB24289.1; AAH58902.1; AAD14150.1; AAH50369.1; AAC50719.1;
Genbank nucleotide ID	NM_005225.2
Ensembl protein ID	ENSP00000345571
Ensembl nucleotide ID	ENSG00000101412
Gene name	Transcription factor E2F1
Gene symbol	E2F1
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Manually collected
Reference	25045080
Functional description	Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F1 binds preferentially RB1 in a cell-cycle dependent manner. It can mediate both cell proliferation and TP53/p53-dependent apoptosis. Blocks adipocyte differentiation by binding to specific promoters repressing CEBPA binding to its target gene promoters (PubMed:20176812). Positively regulates transcription of RRP1B (PubMed:20040599).
Sequence	MALAGAPAGG PCAPALEALL GAGALRLLDS SQIVIISAAQ DASAPPAPTG PAAPAAGPCD 60 PDLLLFATPQ APRPTPSAPR PALGRPPVKR RLDLETDHQY LAESSGPARG RGRHPGKGVK 120 SPGEKSRYET SLNLTTKRFL ELLSHSADGV VDLNWAAEVL KVQKRRIYDI TNVLEGIQLI 180 AKKSKNHIQW LGSHTTVGVG GRLEGLTQDL RQLQESEQQL DHLMNICTTQ LRLLSEDTDS 240 QRLAYVTCQD LRSIADPAEQ MVMVIKAPPE TQLQAVDSSE NFQISLKSKQ GPIDVFLCPE 300 ETVGGISPGK TPSQEVTSEE ENRATDSATI VSPPPSSPPS SLTTDPSQSL LSLEQEPLLS 360 RMGSLRAPVD EDRLSPLVAA DSLLEHVRED FSGLLPEEFI SLSPPHEALD YHFGLEEGEG 420 IRDLFDCDFG DLTPLDF 437

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1H24
1O9K
2AZE
5M9N
5M9O
6G0P
1O9K

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Developmental stage	Species	Evidence	Details
1:1 ortholog	E2F1		A0A452ESG5		Capra hircus	Prediction	More>>
1:1 ortholog	E2F1	1869	Q01094		Homo sapiens	Publication	More>>
1:1 ortholog	E2f1	13555	Q9CYB4	E12.5, E13.5, E14.5	Mus musculus	Prediction	More>>
1:1 ortholog	E2f1	399489	O09139		Rattus norvegicus	Prediction	More>>

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
E2F1	rs2071054C>T	Genotyping	25045080

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1329261524	p.Gly5Arg	missense variant	-	NC_000020.11:g.33686252C>T	gnomAD
rs1467155271	p.Ala6Ser	missense variant	-	NC_000020.11:g.33686249C>A	TOPMed,gnomAD
rs1463146837	p.Pro7Ser	missense variant	-	NC_000020.11:g.33686246G>A	TOPMed
rs974575261	p.Ala8Glu	missense variant	-	NC_000020.11:g.33686242G>T	TOPMed,gnomAD
rs974575261	p.Ala8Val	missense variant	-	NC_000020.11:g.33686242G>A	TOPMed,gnomAD
rs1397093511	p.Gly9Asp	missense variant	-	NC_000020.11:g.33686239C>T	TOPMed,gnomAD
rs1336775242	p.Pro11Ala	missense variant	-	NC_000020.11:g.33686234G>C	TOPMed
rs574523664	p.Cys12Ser	missense variant	-	NC_000020.11:g.33686231A>T	1000Genomes,ExAC,TOPMed,gnomAD
rs574523664	p.Cys12Arg	missense variant	-	NC_000020.11:g.33686231A>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1281052952	p.Ala15Val	missense variant	-	NC_000020.11:g.33686221G>A	gnomAD
rs1185589452	p.Glu17Val	missense variant	-	NC_000020.11:g.33686215T>A	TOPMed,gnomAD
rs1019744956	p.Gly21Arg	missense variant	-	NC_000020.11:g.33686204C>G	TOPMed
rs1367513756	p.Gly23Asp	missense variant	-	NC_000020.11:g.33686197C>T	gnomAD
rs1405640419	p.Gly23Ser	missense variant	-	NC_000020.11:g.33686198C>T	TOPMed,gnomAD
rs1237692050	p.Ala24Thr	missense variant	-	NC_000020.11:g.33686195C>T	gnomAD
rs1405256181	p.Leu25Pro	missense variant	-	NC_000020.11:g.33686191A>G	gnomAD
rs1386191320	p.Arg26Trp	missense variant	-	NC_000020.11:g.33686189G>A	gnomAD
rs1160676980	p.Leu28Phe	missense variant	-	NC_000020.11:g.33686183G>A	gnomAD
rs1008300493	p.Asp29Glu	missense variant	-	NC_000020.11:g.33686178G>T	TOPMed
rs1452027367	p.Ser31Ter	stop gained	-	NC_000020.11:g.33686173G>T	gnomAD
rs1456437519	p.Val34Leu	missense variant	-	NC_000020.11:g.33686165C>G	TOPMed
rs1300481628	p.Ile35Val	missense variant	-	NC_000020.11:g.33686162T>C	TOPMed
rs1011962033	p.Ser43Arg	missense variant	-	NC_000020.11:g.33686136G>C	TOPMed
rs1209626586	p.Pro45Ser	missense variant	-	NC_000020.11:g.33686132G>A	gnomAD
rs1354620926	p.Pro48Ser	missense variant	-	NC_000020.11:g.33686123G>A	gnomAD
rs1320649718	p.Ala52Ser	missense variant	-	NC_000020.11:g.33686111C>A	TOPMed
rs1218731737	p.Ala53Thr	missense variant	-	NC_000020.11:g.33686108C>T	TOPMed
rs1252483725	p.Pro54Leu	missense variant	-	NC_000020.11:g.33686104G>A	TOPMed
rs13041707	p.Ala55Ser	missense variant	-	NC_000020.11:g.33686102C>A	gnomAD
rs1045481159	p.Pro58Ser	missense variant	-	NC_000020.11:g.33686093G>A	TOPMed,gnomAD
rs1249387152	p.Pro58Leu	missense variant	-	NC_000020.11:g.33686092G>A	TOPMed
rs940463871	p.Leu65Phe	missense variant	-	NC_000020.11:g.33686072G>A	TOPMed
rs1163948608	p.Pro76Arg	missense variant	-	NC_000020.11:g.33686038G>C	TOPMed,gnomAD
rs907590073	p.Pro76Ser	missense variant	-	NC_000020.11:g.33686039G>A	TOPMed,gnomAD
rs1429701584	p.Ser77Gly	missense variant	-	NC_000020.11:g.33686036T>C	TOPMed
rs1306675586	p.Ala78Ser	missense variant	-	NC_000020.11:g.33686033C>A	TOPMed
rs1415762835	p.Arg80Gln	missense variant	-	NC_000020.11:g.33686026C>T	TOPMed
rs1226199249	p.Ala82Glu	missense variant	-	NC_000020.11:g.33686020G>T	TOPMed
rs930265454	p.Ala82Thr	missense variant	-	NC_000020.11:g.33686021C>T	TOPMed
rs1297124529	p.Leu83Phe	missense variant	-	NC_000020.11:g.33686018G>A	TOPMed
rs1307523848	p.Gly84Ser	missense variant	-	NC_000020.11:g.33686015C>T	TOPMed
rs1447539203	p.Pro87Arg	missense variant	-	NC_000020.11:g.33686005G>C	gnomAD
rs757413708	p.Lys89Arg	missense variant	-	NC_000020.11:g.33680412T>C	ExAC,gnomAD
NCI-TCGA novel	p.Arg90Trp	missense variant	-	NC_000020.11:g.33680410G>A	NCI-TCGA
rs560305222	p.Asp93Glu	missense variant	-	NC_000020.11:g.33680399G>T	1000Genomes,ExAC,TOPMed,gnomAD
rs1445293021	p.Asp93Asn	missense variant	-	NC_000020.11:g.33680401C>T	TOPMed
rs758760049	p.Asp97His	missense variant	-	NC_000020.11:g.33680389C>G	ExAC,gnomAD
COSM3545490	p.His98Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33680386G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Gln99Ter	stop gained	-	NC_000020.11:g.33680383G>A	NCI-TCGA
rs753190783	p.Tyr100Cys	missense variant	-	NC_000020.11:g.33680379T>C	ExAC,gnomAD
rs753190783	p.Tyr100Phe	missense variant	-	NC_000020.11:g.33680379T>A	ExAC,gnomAD
rs1434158366	p.Leu101Pro	missense variant	-	NC_000020.11:g.33680376A>G	TOPMed,gnomAD
rs145741678	p.Ala102Thr	missense variant	-	NC_000020.11:g.33680374C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs747305116	p.Glu103Lys	missense variant	-	NC_000020.11:g.33680371C>T	ExAC,TOPMed,gnomAD
rs577941795	p.Glu103Asp	missense variant	-	NC_000020.11:g.33680369C>G	1000Genomes,ExAC,gnomAD
rs767288307	p.Pro107Arg	missense variant	-	NC_000020.11:g.33680358G>C	ExAC,gnomAD
rs1159129500	p.Ala108Asp	missense variant	-	NC_000020.11:g.33680355G>T	TOPMed
rs1159129500	p.Ala108Val	missense variant	-	NC_000020.11:g.33680355G>A	TOPMed
rs149803612	p.Arg109Trp	missense variant	-	NC_000020.11:g.33680353G>A	ESP,ExAC,TOPMed,gnomAD
rs199740633	p.Arg109Gln	missense variant	-	NC_000020.11:g.33680352C>T	1000Genomes,TOPMed,gnomAD
rs199740633	p.Arg109Pro	missense variant	-	NC_000020.11:g.33680352C>G	1000Genomes,TOPMed,gnomAD
COSM3545488	p.Gly110Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33680350C>T	NCI-TCGA Cosmic
rs774045899	p.Arg113Cys	missense variant	-	NC_000020.11:g.33680341G>A	ExAC,TOPMed,gnomAD
rs768373441	p.Arg113His	missense variant	-	NC_000020.11:g.33680340C>T	ExAC,TOPMed,gnomAD
rs1439667088	p.Pro115Thr	missense variant	-	NC_000020.11:g.33680335G>T	TOPMed
COSM1483556	p.Ser121PhePheSerTerUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000020.11:g.33679965_33679966insA	NCI-TCGA Cosmic
rs200324089	p.Pro122Leu	missense variant	-	NC_000020.11:g.33679962G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs200324089	p.Pro122Gln	missense variant	-	NC_000020.11:g.33679962G>T	1000Genomes,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu124ArgPheSerTerUnk	frameshift	-	NC_000020.11:g.33679957C>-	NCI-TCGA
NCI-TCGA novel	p.Glu124Gln	missense variant	-	NC_000020.11:g.33679957C>G	NCI-TCGA
rs748471303	p.Glu124Gly	missense variant	-	NC_000020.11:g.33679956T>C	ExAC,gnomAD
COSM244178	p.Arg127His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33679947C>T	NCI-TCGA Cosmic
rs1349182634	p.Tyr128Phe	missense variant	-	NC_000020.11:g.33679944T>A	TOPMed,gnomAD
rs779392416	p.Thr130Ser	missense variant	-	NC_000020.11:g.33679938G>C	ExAC,gnomAD
COSM1025974	p.Ser131Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000020.11:g.33679935G>C	NCI-TCGA Cosmic
rs1485295370	p.Asn133Ser	missense variant	-	NC_000020.11:g.33679929T>C	TOPMed
rs755388533	p.Thr135Ile	missense variant	-	NC_000020.11:g.33679923G>A	ExAC,gnomAD
COSM2757824	p.Arg138Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33679915G>A	NCI-TCGA Cosmic
COSM1025973	p.Ser144Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33679897T>G	NCI-TCGA Cosmic
rs751015434	p.Ala147Val	missense variant	-	NC_000020.11:g.33679887G>A	ExAC,gnomAD
NCI-TCGA novel	p.Asp148ValPheSerTerUnk	frameshift	-	NC_000020.11:g.33679881_33679884CCGT>-	NCI-TCGA
COSM724002	p.Asp148Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33679885C>T	NCI-TCGA Cosmic
rs752291306	p.Val151Ala	missense variant	-	NC_000020.11:g.33679875A>G	ExAC,gnomAD
rs758127423	p.Val151Ile	missense variant	-	NC_000020.11:g.33679876C>T	ExAC,gnomAD
rs759306871	p.Glu158Lys	missense variant	-	NC_000020.11:g.33679855C>T	ExAC,gnomAD
rs371120550	p.Val159Met	missense variant	-	NC_000020.11:g.33679852C>T	ESP,ExAC,TOPMed,gnomAD
COSM577076	p.Arg165Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33679833C>T	NCI-TCGA Cosmic
COSM443676	p.Arg165Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33679834G>A	NCI-TCGA Cosmic
rs864622017	p.Arg166His	missense variant	-	NC_000020.11:g.33679830C>T	-
RCV000204567	p.Arg166His	missense variant	Malignant tumor of prostate	NC_000020.11:g.33679830C>T	ClinVar
COSM443675	p.Tyr168Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33679824T>C	NCI-TCGA Cosmic
rs1413440731	p.Asn172Ser	missense variant	-	NC_000020.11:g.33679812T>C	TOPMed
NCI-TCGA novel	p.Leu174Ile	missense variant	-	NC_000020.11:g.33679807G>T	NCI-TCGA
rs377425346	p.Ile180Val	missense variant	-	NC_000020.11:g.33679789T>C	ESP,ExAC,gnomAD
NCI-TCGA novel	p.Lys185GluPheSerTerUnkUnk	frameshift	-	NC_000020.11:g.33679773_33679774TT>-	NCI-TCGA
COSM3545487	p.Gln189Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000020.11:g.33679762G>A	NCI-TCGA Cosmic
rs776055929	p.Gly192Ala	missense variant	-	NC_000020.11:g.33678351C>G	ExAC,gnomAD
rs1315185562	p.Ser193Arg	missense variant	-	NC_000020.11:g.33678347G>C	TOPMed,gnomAD
rs770049550	p.His194Tyr	missense variant	-	NC_000020.11:g.33678346G>A	ExAC,gnomAD
rs771638059	p.Val199Ile	missense variant	-	NC_000020.11:g.33678331C>T	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Val199Ala	missense variant	-	NC_000020.11:g.33678330A>G	NCI-TCGA
rs771638059	p.Val199Phe	missense variant	-	NC_000020.11:g.33678331C>A	ExAC,TOPMed,gnomAD
rs754564586	p.Gly200Asp	missense variant	-	NC_000020.11:g.33678327C>T	ExAC,gnomAD
rs35385772	p.Gly200Ser	missense variant	-	NC_000020.11:g.33678328C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs35385772	p.Gly200Ser	missense variant	-	NC_000020.11:g.33678328C>T	UniProt,dbSNP
VAR_048907	p.Gly200Ser	missense variant	-	NC_000020.11:g.33678328C>T	UniProt
rs753472103	p.Gly201Arg	missense variant	-	NC_000020.11:g.33678325C>T	ExAC,gnomAD
rs373902244	p.Arg202Gln	missense variant	-	NC_000020.11:g.33678321C>T	ESP,ExAC,TOPMed,gnomAD
rs377637237	p.Arg202Trp	missense variant	-	NC_000020.11:g.33678322G>A	ESP,ExAC,TOPMed,gnomAD
rs546049774	p.Leu203His	missense variant	-	NC_000020.11:g.33678318A>T	1000Genomes,gnomAD
rs750422437	p.Gly205Glu	missense variant	-	NC_000020.11:g.33678312C>T	ExAC,gnomAD
rs1273903227	p.Leu206Trp	missense variant	-	NC_000020.11:g.33678309A>C	gnomAD
NCI-TCGA novel	p.Gln208Leu	missense variant	-	NC_000020.11:g.33678303T>A	NCI-TCGA
NCI-TCGA novel	p.Gln208His	missense variant	-	NC_000020.11:g.33678302C>A	NCI-TCGA
rs1463764539	p.Gln208Arg	missense variant	-	NC_000020.11:g.33678303T>C	TOPMed
rs767306081	p.Arg211Gln	missense variant	-	NC_000020.11:g.33678294C>T	ExAC,TOPMed,gnomAD
rs1223127537	p.Arg211Ter	stop gained	-	NC_000020.11:g.33678295G>A	gnomAD
rs200658903	p.Gln212Leu	missense variant	-	NC_000020.11:g.33678291T>A	ESP,ExAC,TOPMed,gnomAD
rs764256438	p.Ser216Asn	missense variant	-	NC_000020.11:g.33678279C>T	ExAC,gnomAD
rs1411810755	p.His222Arg	missense variant	-	NC_000020.11:g.33678261T>C	gnomAD
rs199745489	p.Met224Ile	missense variant	-	NC_000020.11:g.33678254C>T	ESP,ExAC,TOPMed,gnomAD
rs1308009438	p.Met224Thr	missense variant	-	NC_000020.11:g.33678255A>G	gnomAD
rs1161856955	p.Asn225Ser	missense variant	-	NC_000020.11:g.33678252T>C	gnomAD
rs759773652	p.Asn225Asp	missense variant	-	NC_000020.11:g.33678253T>C	ExAC,TOPMed,gnomAD
COSM724004	p.Cys227Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33678246C>A	NCI-TCGA Cosmic
rs771273717	p.Thr229Met	missense variant	-	NC_000020.11:g.33678240G>A	ExAC,TOPMed,gnomAD
rs771273717	p.Thr229Arg	missense variant	-	NC_000020.11:g.33678240G>C	ExAC,TOPMed,gnomAD
rs771273717	p.Thr229Lys	missense variant	-	NC_000020.11:g.33678240G>T	ExAC,TOPMed,gnomAD
rs201920937	p.Gln230His	missense variant	-	NC_000020.11:g.33678236C>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gln230Ter	stop gained	-	NC_000020.11:g.33678238G>A	NCI-TCGA
rs1372237664	p.Arg232His	missense variant	-	NC_000020.11:g.33678231C>T	TOPMed
rs531113927	p.Arg232Cys	missense variant	-	NC_000020.11:g.33678232G>A	1000Genomes,ExAC,gnomAD
rs1200120018	p.Glu236Lys	missense variant	-	NC_000020.11:g.33678220C>T	gnomAD
rs1453289243	p.Asp237Val	missense variant	-	NC_000020.11:g.33678216T>A	gnomAD
rs1217897911	p.Thr238Asn	missense variant	-	NC_000020.11:g.33678213G>T	gnomAD
NCI-TCGA novel	p.Ser240Asn	missense variant	-	NC_000020.11:g.33678207C>T	NCI-TCGA
NCI-TCGA novel	p.Gln241Ter	stop gained	-	NC_000020.11:g.33678205G>A	NCI-TCGA
rs745608299	p.Arg242His	missense variant	-	NC_000020.11:g.33678201C>T	ExAC,gnomAD
COSM1025970	p.Val246Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677529A>G	NCI-TCGA Cosmic
rs913895798	p.Thr247Met	missense variant	-	NC_000020.11:g.33677526G>A	gnomAD
rs376645897	p.Gln249Glu	missense variant	-	NC_000020.11:g.33677521G>C	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Asp250Asn	missense variant	-	NC_000020.11:g.33677518C>T	NCI-TCGA
rs3213172	p.Arg252His	missense variant	-	NC_000020.11:g.33677511C>T	ExAC,TOPMed,gnomAD
COSM122751	p.Arg252Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677512G>A	NCI-TCGA Cosmic
rs373383167	p.Ile254Thr	missense variant	-	NC_000020.11:g.33677505A>G	ESP,ExAC,gnomAD
rs1448591564	p.Ala255Val	missense variant	-	NC_000020.11:g.33677502G>A	TOPMed,gnomAD
rs1448591564	p.Ala255Gly	missense variant	-	NC_000020.11:g.33677502G>C	TOPMed,gnomAD
rs758585438	p.Asp256Asn	missense variant	-	NC_000020.11:g.33677500C>T	ExAC,TOPMed,gnomAD
rs758585438	p.Asp256His	missense variant	-	NC_000020.11:g.33677500C>G	ExAC,TOPMed,gnomAD
rs34468325	p.Glu259Asp	missense variant	-	NC_000020.11:g.33677489C>A	ESP,ExAC,TOPMed,gnomAD
rs1444239480	p.Gln260Arg	missense variant	-	NC_000020.11:g.33677487T>C	gnomAD
rs765506787	p.Val262Ile	missense variant	-	NC_000020.11:g.33677482C>T	ExAC,gnomAD
rs1370578502	p.Met263Leu	missense variant	-	NC_000020.11:g.33677479T>G	TOPMed
rs1199894772	p.Val264Leu	missense variant	-	NC_000020.11:g.33677476C>G	TOPMed,gnomAD
rs755210188	p.Lys266Arg	missense variant	-	NC_000020.11:g.33677469T>C	ExAC,TOPMed,gnomAD
rs1226721709	p.Ala267Val	missense variant	-	NC_000020.11:g.33677466G>A	gnomAD
rs1300371237	p.Ala267Thr	missense variant	-	NC_000020.11:g.33677467C>T	gnomAD
NCI-TCGA novel	p.Pro268Ala	missense variant	-	NC_000020.11:g.33677464G>C	NCI-TCGA
rs917803687	p.Pro269Arg	missense variant	-	NC_000020.11:g.33677460G>C	TOPMed
rs541956472	p.Gln272His	missense variant	-	NC_000020.11:g.33677450C>G	1000Genomes,ExAC,gnomAD
COSM4915933	p.Gln272Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677451T>A	NCI-TCGA Cosmic
rs3213173	p.Val276Met	missense variant	-	NC_000020.11:g.33677440C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1409977256	p.Asp277His	missense variant	-	NC_000020.11:g.33677437C>G	TOPMed,gnomAD
rs1409977256	p.Asp277Tyr	missense variant	-	NC_000020.11:g.33677437C>A	TOPMed,gnomAD
rs767969405	p.Ser279Pro	missense variant	-	NC_000020.11:g.33677431A>G	ExAC,gnomAD
rs183250565	p.Ser279Leu	missense variant	-	NC_000020.11:g.33677430G>A	1000Genomes,TOPMed,gnomAD
COSM1025969	p.Glu280Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677428C>G	NCI-TCGA Cosmic
rs1411968038	p.Leu286Phe	missense variant	-	NC_000020.11:g.33677315G>A	TOPMed,gnomAD
rs1254039207	p.Lys289Gln	missense variant	-	NC_000020.11:g.33677306T>G	gnomAD
rs1031106445	p.Gln290Arg	missense variant	-	NC_000020.11:g.33677302T>C	TOPMed
NCI-TCGA novel	p.Gly291Val	missense variant	-	NC_000020.11:g.33677299C>A	NCI-TCGA
rs867122904	p.Pro292Leu	missense variant	-	NC_000020.11:g.33677296G>A	TOPMed
rs1483031461	p.Ile293Val	missense variant	-	NC_000020.11:g.33677294T>C	gnomAD
rs752075116	p.Asp294Glu	missense variant	-	NC_000020.11:g.33677289A>T	ExAC,gnomAD
rs762296081	p.Asp294Asn	missense variant	-	NC_000020.11:g.33677291C>T	ExAC,TOPMed,gnomAD
COSM1025967	p.Val295Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677287A>T	NCI-TCGA Cosmic
COSM1025966	p.Pro299His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677275G>T	NCI-TCGA Cosmic
rs1330667209	p.Thr302Ser	missense variant	-	NC_000020.11:g.33677267T>A	gnomAD
rs770643353	p.Val303Ile	missense variant	-	NC_000020.11:g.33677264C>T	ExAC,TOPMed,gnomAD
rs1295204827	p.Ile306Asn	missense variant	-	NC_000020.11:g.33677254A>T	TOPMed,gnomAD
COSM6092803	p.Ile306Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677255T>C	NCI-TCGA Cosmic
rs773197012	p.Pro308Ser	missense variant	-	NC_000020.11:g.33677249G>A	ExAC,gnomAD
rs535573433	p.Gly309Glu	missense variant	-	NC_000020.11:g.33677245C>T	1000Genomes,ExAC,gnomAD
rs3213174	p.Thr311Asn	missense variant	-	NC_000020.11:g.33677239G>T	ESP,ExAC,TOPMed,gnomAD
rs778884599	p.Pro312Leu	missense variant	-	NC_000020.11:g.33677236G>A	ExAC,TOPMed,gnomAD
rs768640915	p.Ser313Pro	missense variant	-	NC_000020.11:g.33677234A>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gln314His	missense variant	-	NC_000020.11:g.33677229C>A	NCI-TCGA
rs749348639	p.Ser318Phe	missense variant	-	NC_000020.11:g.33677218G>A	ExAC
rs1163087475	p.Ser318Thr	missense variant	-	NC_000020.11:g.33677219A>T	TOPMed,gnomAD
NCI-TCGA novel	p.Glu320Ter	stop gained	-	NC_000020.11:g.33677213C>A	NCI-TCGA
COSM1025965	p.Glu321Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677208C>A	NCI-TCGA Cosmic
rs1426219585	p.Asn322Tyr	missense variant	-	NC_000020.11:g.33677207T>A	gnomAD
rs144481343	p.Arg323Lys	missense variant	-	NC_000020.11:g.33677203C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs553413048	p.Ala324Thr	missense variant	-	NC_000020.11:g.33677201C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs1437203114	p.Ala324Gly	missense variant	-	NC_000020.11:g.33677200G>C	gnomAD
rs1218719606	p.Ser327Cys	missense variant	-	NC_000020.11:g.33677191G>C	TOPMed
rs1276667126	p.Ala328Gly	missense variant	-	NC_000020.11:g.33677188G>C	TOPMed
rs1209699253	p.Val331Leu	missense variant	-	NC_000020.11:g.33677180C>G	gnomAD
rs1331442679	p.Pro334Ser	missense variant	-	NC_000020.11:g.33677171G>A	TOPMed
rs750641087	p.Pro334Gln	missense variant	-	NC_000020.11:g.33677170G>T	ExAC,gnomAD
rs1227306281	p.Pro335Arg	missense variant	-	NC_000020.11:g.33677167G>C	gnomAD
rs149272498	p.Pro335Ala	missense variant	-	NC_000020.11:g.33677168G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1268470913	p.Ser336Pro	missense variant	-	NC_000020.11:g.33677165A>G	TOPMed
rs757620294	p.Pro338Ser	missense variant	-	NC_000020.11:g.33677159G>A	ExAC,gnomAD
rs764626563	p.Pro339Leu	missense variant	-	NC_000020.11:g.33677155G>A	ExAC,TOPMed,gnomAD
rs752029737	p.Pro339Ala	missense variant	-	NC_000020.11:g.33677156G>C	ExAC,gnomAD
NCI-TCGA novel	p.Ser340LeuPheSerTerUnkUnk	frameshift	-	NC_000020.11:g.33677153_33677154insG	NCI-TCGA
rs1478347951	p.Ser340Leu	missense variant	-	NC_000020.11:g.33677152G>A	TOPMed
rs765976516	p.Thr343Pro	missense variant	-	NC_000020.11:g.33677144T>G	ExAC,gnomAD
rs564825532	p.Thr343Ile	missense variant	-	NC_000020.11:g.33677143G>A	ExAC,gnomAD
rs771807428	p.Thr344Arg	missense variant	-	NC_000020.11:g.33677140G>C	ExAC,gnomAD
rs761616906	p.Asp345Gly	missense variant	-	NC_000020.11:g.33677137T>C	ExAC,gnomAD
rs145759508	p.Pro346Ser	missense variant	-	NC_000020.11:g.33677135G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
COSM3545484	p.Pro346Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33677134G>A	NCI-TCGA Cosmic
rs1458453215	p.Ser349Tyr	missense variant	-	NC_000020.11:g.33677125G>T	TOPMed
rs749340138	p.Leu350Val	missense variant	-	NC_000020.11:g.33677123G>C	ExAC,TOPMed,gnomAD
rs745908531	p.Pro357Leu	missense variant	-	NC_000020.11:g.33676976G>A	ExAC,TOPMed,gnomAD
rs747187347	p.Arg361Trp	missense variant	-	NC_000020.11:g.33676965G>A	ExAC,gnomAD
rs778271263	p.Arg361Gln	missense variant	-	NC_000020.11:g.33676964C>T	ExAC,TOPMed,gnomAD
rs778271263	p.Arg361Pro	missense variant	-	NC_000020.11:g.33676964C>G	ExAC,TOPMed,gnomAD
rs1167700961	p.Gly363Cys	missense variant	-	NC_000020.11:g.33676959C>A	gnomAD
COSM1307298	p.Gly363Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33676959C>G	NCI-TCGA Cosmic
rs1392564339	p.Leu365Pro	missense variant	-	NC_000020.11:g.33676952A>G	TOPMed
rs755713339	p.Arg366Gln	missense variant	-	NC_000020.11:g.33676949C>T	ExAC,TOPMed,gnomAD
rs779509637	p.Arg366Trp	missense variant	-	NC_000020.11:g.33676950G>A	ExAC,gnomAD
rs755713339	p.Arg366Leu	missense variant	-	NC_000020.11:g.33676949C>A	ExAC,TOPMed,gnomAD
rs1183655268	p.Ala367Thr	missense variant	-	NC_000020.11:g.33676947C>T	gnomAD
rs1249650575	p.Pro368Ser	missense variant	-	NC_000020.11:g.33676944G>A	gnomAD
NCI-TCGA novel	p.Pro368Leu	missense variant	-	NC_000020.11:g.33676943G>A	NCI-TCGA
rs367723468	p.Val369Leu	missense variant	-	NC_000020.11:g.33676941C>G	ESP,ExAC,TOPMed,gnomAD
rs367723468	p.Val369Met	missense variant	-	NC_000020.11:g.33676941C>T	ESP,ExAC,TOPMed,gnomAD
rs373587139	p.Glu371Lys	missense variant	-	NC_000020.11:g.33676935C>T	ESP,ExAC,TOPMed,gnomAD
rs762689168	p.Glu371Asp	missense variant	-	NC_000020.11:g.33676933C>A	ExAC,gnomAD
rs1230230127	p.Asp372Asn	missense variant	-	NC_000020.11:g.33676932C>T	gnomAD
rs915788985	p.Arg373Cys	missense variant	-	NC_000020.11:g.33676929G>A	TOPMed,gnomAD
rs796465642	p.Arg373His	missense variant	-	NC_000020.11:g.33676928C>T	TOPMed,gnomAD
rs796465642	p.Arg373Leu	missense variant	-	NC_000020.11:g.33676928C>A	TOPMed,gnomAD
rs1387771403	p.Pro376Leu	missense variant	-	NC_000020.11:g.33676919G>A	TOPMed,gnomAD
rs371155232	p.Val378Met	missense variant	-	NC_000020.11:g.33676914C>T	ESP,ExAC,TOPMed,gnomAD
rs371155232	p.Val378Leu	missense variant	-	NC_000020.11:g.33676914C>A	ESP,ExAC,TOPMed,gnomAD
rs371155232	p.Val378Leu	missense variant	-	NC_000020.11:g.33676914C>G	ESP,ExAC,TOPMed,gnomAD
rs1412203811	p.Val378Glu	missense variant	-	NC_000020.11:g.33676913A>T	gnomAD
rs1160751229	p.Ala379Val	missense variant	-	NC_000020.11:g.33676910G>A	gnomAD
rs770915873	p.Ala380Val	missense variant	-	NC_000020.11:g.33676907G>A	ExAC,gnomAD
rs1453160857	p.Asp381Asn	missense variant	-	NC_000020.11:g.33676905C>T	TOPMed,gnomAD
rs773280034	p.Ser382Leu	missense variant	-	NC_000020.11:g.33676901G>A	ExAC,TOPMed,gnomAD
rs748480309	p.Glu385Asp	missense variant	-	NC_000020.11:g.33676891C>A	ExAC,TOPMed,gnomAD
rs1182100979	p.Glu385Gln	missense variant	-	NC_000020.11:g.33676893C>G	TOPMed
rs779566653	p.Arg388Trp	missense variant	-	NC_000020.11:g.33676884G>A	ExAC,gnomAD
rs769226220	p.Arg388Leu	missense variant	-	NC_000020.11:g.33676883C>A	ExAC,gnomAD
rs769226220	p.Arg388Gln	missense variant	-	NC_000020.11:g.33676883C>T	ExAC,gnomAD
rs560760846	p.Glu389Lys	missense variant	-	NC_000020.11:g.33676881C>T	1000Genomes,ExAC,gnomAD
rs1333288110	p.Phe391Leu	missense variant	-	NC_000020.11:g.33676873G>C	TOPMed,gnomAD
rs760692854	p.Ser392Tyr	missense variant	-	NC_000020.11:g.33676871G>T	gnomAD
rs3213176	p.Gly393Ser	missense variant	-	NC_000020.11:g.33676869C>T	1000Genomes,ESP,TOPMed,gnomAD
rs1322122446	p.Leu395Phe	missense variant	-	NC_000020.11:g.33676863G>A	TOPMed,gnomAD
rs751247203	p.Glu398Lys	missense variant	-	NC_000020.11:g.33676854C>T	ExAC,gnomAD
rs1450772669	p.Ile400Phe	missense variant	-	NC_000020.11:g.33676848T>A	TOPMed
rs1346488069	p.Leu402Phe	missense variant	-	NC_000020.11:g.33676842G>A	gnomAD
rs373228968	p.His406Asp	missense variant	-	NC_000020.11:g.33676830G>C	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.His406Pro	missense variant	-	NC_000020.11:g.33676829T>G	NCI-TCGA
rs553240434	p.His406Gln	missense variant	-	NC_000020.11:g.33676828G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs373228968	p.His406Asn	missense variant	-	NC_000020.11:g.33676830G>T	ESP,ExAC,TOPMed,gnomAD
rs373228968	p.His406Tyr	missense variant	-	NC_000020.11:g.33676830G>A	ESP,ExAC,TOPMed,gnomAD
rs1210786388	p.Glu407Lys	missense variant	-	NC_000020.11:g.33676827C>T	gnomAD
rs1278743140	p.Asp410Glu	missense variant	-	NC_000020.11:g.33676816G>C	gnomAD
rs760618502	p.Asp410Asn	missense variant	-	NC_000020.11:g.33676818C>T	ExAC,TOPMed,gnomAD
rs1234094782	p.Tyr411His	missense variant	-	NC_000020.11:g.33676815A>G	gnomAD
rs1012010770	p.His412Gln	missense variant	-	NC_000020.11:g.33676810G>T	TOPMed
rs535111025	p.Phe413Leu	missense variant	-	NC_000020.11:g.33676807G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs1299418903	p.Phe413Leu	missense variant	-	NC_000020.11:g.33676809A>G	gnomAD
NCI-TCGA novel	p.Gly414Ser	missense variant	-	NC_000020.11:g.33676806C>T	NCI-TCGA
rs772350151	p.Leu415Phe	missense variant	-	NC_000020.11:g.33676803G>A	ExAC,gnomAD
rs1400047527	p.Glu416Lys	missense variant	-	NC_000020.11:g.33676800C>T	gnomAD
rs1400047527	p.Glu416Gln	missense variant	-	NC_000020.11:g.33676800C>G	gnomAD
rs774912473	p.Gly418Ser	missense variant	-	NC_000020.11:g.33676794C>T	ExAC,gnomAD
rs1465634263	p.Glu419Lys	missense variant	-	NC_000020.11:g.33676791C>T	TOPMed
rs749840514	p.Gly420Asp	missense variant	-	NC_000020.11:g.33676787C>T	ExAC,gnomAD
rs1241680411	p.Ile421Val	missense variant	-	NC_000020.11:g.33676785T>C	gnomAD
NCI-TCGA novel	p.Leu424Arg	missense variant	-	NC_000020.11:g.33676775A>C	NCI-TCGA
NCI-TCGA novel	p.Phe425ThrPheSerTerUnkUnk	frameshift	-	NC_000020.11:g.33676755_33676773CCCCAAAGTCACAGTCGAA>-	NCI-TCGA
rs777420006	p.Asp426His	missense variant	-	NC_000020.11:g.33676770C>G	ExAC,TOPMed,gnomAD
rs777420006	p.Asp426Asn	missense variant	-	NC_000020.11:g.33676770C>T	ExAC,TOPMed,gnomAD
rs1277250317	p.Cys427Arg	missense variant	-	NC_000020.11:g.33676767A>G	gnomAD
rs758107340	p.Phe429Tyr	missense variant	-	NC_000020.11:g.33676760A>T	ExAC,gnomAD
rs1284406098	p.Gly430Glu	missense variant	-	NC_000020.11:g.33676757C>T	gnomAD
rs1449665581	p.Asp431Asn	missense variant	-	NC_000020.11:g.33676755C>T	gnomAD
rs1312246924	p.Thr433Ala	missense variant	-	NC_000020.11:g.33676749T>C	gnomAD
rs151195835	p.Thr433Asn	missense variant	-	NC_000020.11:g.33676748G>T	ESP,ExAC,gnomAD
rs151195835	p.Thr433Ile	missense variant	-	NC_000020.11:g.33676748G>A	ESP,ExAC,gnomAD
rs267605891	p.Pro434Arg	missense variant	-	NC_000020.11:g.33676745G>C	ESP,ExAC,TOPMed,gnomAD
rs267605891	p.Pro434Leu	missense variant	-	NC_000020.11:g.33676745G>A	ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Leu435TrpPheSerTerUnkUnk	frameshift	-	NC_000020.11:g.33676743G>-	NCI-TCGA
COSM6159347	p.Phe437Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000020.11:g.33676735G>C	NCI-TCGA Cosmic
rs766184341	p.Ter438Trp	stop lost	-	NC_000020.11:g.33676732T>C	ExAC,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE;LHGDN
C0001486	Adenovirus Infections	group	BEFREE
C0002395	Alzheimer's Disease	disease	BEFREE;LHGDN
C0002726	Amyloidosis	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004135	Ataxia Telangiectasia	disease	LHGDN
C0004509	Azoospermia	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE
C0006118	Brain Neoplasms	group	BEFREE;LHGDN
C0006142	Malignant neoplasm of breast	disease	BEFREE;CTD_human
C0006413	Burkitt Lymphoma	disease	BEFREE
C0006826	Malignant Neoplasms	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007121	Bronchogenic Carcinoma	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE;LHGDN
C0007137	Squamous cell carcinoma	disease	BEFREE
C0007138	Carcinoma, Transitional Cell	disease	BEFREE
C0007847	Malignant tumor of cervix	disease	BEFREE
C0007873	Uterine Cervical Neoplasm	disease	LHGDN
C0009375	Colonic Neoplasms	group	LHGDN
C0009402	Colorectal Carcinoma	disease	BEFREE
C0011265	Presenile dementia	disease	BEFREE
C0011854	Diabetes Mellitus, Insulin-Dependent	disease	MGD
C0011875	Diabetic Angiopathies	disease	LHGDN
C0011881	Diabetic Nephropathy	disease	BEFREE
C0013080	Down Syndrome	disease	BEFREE
C0013264	Muscular Dystrophy, Duchenne	disease	BEFREE
C0014070	Encephalomyelitis	disease	BEFREE
C0014859	Esophageal Neoplasms	group	BEFREE
C0015625	Fanconi Anemia	disease	BEFREE
C0015672	Fatigue	phenotype	BEFREE
C0016057	Fibrosarcoma	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE;LHGDN
C0018790	Cardiac Arrest	disease	BEFREE
C0019163	Hepatitis B	disease	BEFREE
C0019196	Hepatitis C	disease	LHGDN
C0020179	Huntington Disease	disease	RGD
C0020255	Hydrocephalus	disease	BEFREE
C0021367	Mammary Ductal Carcinoma	disease	BEFREE
C0021400	Influenza	disease	BEFREE
C0022665	Kidney Neoplasm	disease	BEFREE
C0023434	Chronic Lymphocytic Leukemia	disease	BEFREE
C0023448	Lymphoid leukemia	disease	BEFREE
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE
C0023827	liposarcoma	disease	BEFREE
C0023903	Liver neoplasms	group	BEFREE;LHGDN
C0024121	Lung Neoplasms	group	BEFREE
C0024299	Lymphoma	group	BEFREE
C0024305	Lymphoma, Non-Hodgkin	disease	LHGDN
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025149	Medulloblastoma	disease	BEFREE
C0025202	melanoma	disease	BEFREE;CTD_human;LHGDN
C0025500	Mesothelioma	disease	BEFREE
C0026010	Microphthalmos	disease	BEFREE
C0026640	Mouth Neoplasms	group	LHGDN
C0026764	Multiple Myeloma	disease	BEFREE
C0026948	Mycosis Fungoides	group	BEFREE
C0027019	Myelomonocytic leukemia	disease	BEFREE
C0027051	Myocardial Infarction	disease	BEFREE
C0027126	Myotonic Dystrophy	disease	BEFREE
C0027533	Neck Neoplasms	group	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027651	Neoplasms	group	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030354	Papilloma	disease	BEFREE
C0030567	Parkinson Disease	disease	BEFREE;LHGDN
C0032000	Pituitary Adenoma	disease	BEFREE
C0032002	Pituitary Diseases	group	BEFREE
C0032019	Pituitary Neoplasms	group	BEFREE
C0032584	polyps	phenotype	BEFREE
C0032927	Precancerous Conditions	group	BEFREE
C0033375	Prolactinoma	disease	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE;LHGDN
C0035335	Retinoblastoma	disease	BEFREE
C0037286	Skin Neoplasms	group	BEFREE
C0038356	Stomach Neoplasms	group	LHGDN
C0040034	Thrombocytopenia	phenotype	BEFREE
C0040136	Thyroid Neoplasm	disease	BEFREE
C0042109	Urticaria	disease	BEFREE
C0079744	Diffuse Large B-Cell Lymphoma	disease	BEFREE
C0085110	Severe Combined Immunodeficiency	disease	BEFREE
C0085281	Addictive Behavior	phenotype	BEFREE
C0086981	Sicca Syndrome	disease	MGD
C0149782	Squamous cell carcinoma of lung	disease	BEFREE
C0149925	Small cell carcinoma of lung	disease	BEFREE
C0151468	Thyroid Gland Follicular Adenoma	disease	BEFREE
C0151779	Cutaneous Melanoma	disease	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152018	Esophageal carcinoma	disease	BEFREE
C0153633	Malignant neoplasm of brain	disease	BEFREE
C0156312	Atrophy of testis	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0205647	Follicular adenoma	disease	BEFREE
C0206093	Neuroectodermal Tumors	disease	BEFREE
C0206655	Alveolar rhabdomyosarcoma	disease	BEFREE
C0206663	Neuroectodermal Tumor, Primitive	disease	BEFREE
C0206682	Follicular thyroid carcinoma	disease	BEFREE
C0206743	Rhabdoid Tumor	disease	BEFREE
C0220633	Uveal melanoma	disease	BEFREE
C0221232	Welts	phenotype	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238198	Gastrointestinal Stromal Tumors	group	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0263641	Epithelial hyperplasia of skin	disease	BEFREE
C0272138	Erythroblastosis	disease	BEFREE
C0275524	Coinfection	phenotype	BEFREE
C0276548	HIV encephalitis	disease	BEFREE
C0278484	Malignant neoplasm of colon stage IV	disease	BEFREE
C0278838	Prostate cancer recurrent	disease	BEFREE
C0278883	Metastatic melanoma	disease	BEFREE
C0279000	Liver and Intrahepatic Biliary Tract Carcinoma	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0279702	Conventional (Clear Cell) Renal Cell Carcinoma	disease	BEFREE
C0280313	Squamous cell carcinoma of oropharynx	disease	BEFREE
C0302592	Cervix carcinoma	disease	BEFREE
C0334634	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	disease	BEFREE
C0338106	Adenocarcinoma of colon	disease	BEFREE
C0345904	Malignant neoplasm of liver	disease	BEFREE
C0346429	Multiple malignancy	phenotype	BEFREE
C0346629	Malignant neoplasm of large intestine	disease	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0392514	Hereditary hemochromatosis	disease	BEFREE
C0424295	Hyperactive behavior	phenotype	BEFREE
C0494165	Secondary malignant neoplasm of liver	disease	BEFREE
C0497327	Dementia	disease	BEFREE;LHGDN
C0521158	Recurrent tumor	phenotype	BEFREE
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0555198	Malignant Glioma	disease	BEFREE
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598766	Leukemogenesis	disease	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE;CTD_human
C0679427	myeloblastosis	disease	BEFREE
C0684249	Carcinoma of lung	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0919267	ovarian neoplasm	disease	BEFREE;LHGDN
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1257931	Mammary Neoplasms, Human	group	CTD_human
C1258666	Myxoid cyst	disease	BEFREE
C1261473	Sarcoma	group	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1319315	Adenocarcinoma of large intestine	disease	BEFREE
C1335302	Pancreatic Ductal Adenocarcinoma	disease	BEFREE
C1336077	Sporadic Burkitt's lymphoma	disease	BEFREE
C1337012	Well-differentiated papillary mesothelioma	disease	BEFREE
C1377610	Peritoneal Mesothelioma	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;CTD_human;LHGDN
C1510885	Angiogenic Switch	disease	BEFREE
C1512409	Hepatocarcinogenesis	disease	BEFREE
C1519680	Tumor Immunity	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1527336	Sjogren's Syndrome	disease	MGD
C1527349	Ductal Breast Carcinoma	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1861305	TARSAL-CARPAL COALITION SYNDROME	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE;CTD_human
C2349952	Oropharyngeal Carcinoma	disease	BEFREE
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C3179349	Gastrointestinal Stromal Sarcoma	disease	BEFREE
C3463824	MYELODYSPLASTIC SYNDROME	group	BEFREE;LHGDN
C3469521	FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)	disease	BEFREE
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3714514	Infection	group	LHGDN
C3887461	Head and Neck Carcinoma	disease	BEFREE
C4025708	Cerebellar malformation	phenotype	BEFREE
C4048328	cervical cancer	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	ISA
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	ISM
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	IMP
GO:0000981	DNA-binding transcription factor activity, RNA polymerase II-specific	IBA
GO:0000987	cis-regulatory region sequence-specific DNA binding	IDA
GO:0001216	DNA-binding transcription activator activity	IDA
GO:0003677	DNA binding	IMP
GO:0003677	DNA binding	IDA
GO:0003677	DNA binding	IBA
GO:0003700	DNA-binding transcription factor activity	TAS
GO:0003700	DNA-binding transcription factor activity	IDA
GO:0003700	DNA-binding transcription factor activity	IBA
GO:0005515	protein binding	IPI
GO:0008134	transcription factor binding	IPI
GO:0008134	transcription factor binding	IBA
GO:0019901	protein kinase binding	IEA
GO:0043565	sequence-specific DNA binding	ISS
GO:0043565	sequence-specific DNA binding	IBA
GO:0043565	sequence-specific DNA binding	IDA
GO:0046983	protein dimerization activity	IEA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000077	DNA damage checkpoint	IMP
GO:0000083	regulation of transcription involved in G1/S transition of mitotic cell cycle	TAS
GO:0000122	negative regulation of transcription by RNA polymerase II	IMP
GO:0000122	negative regulation of transcription by RNA polymerase II	IBA
GO:0006351	transcription, DNA-templated	ISS
GO:0006355	regulation of transcription, DNA-templated	IDA
GO:0006977	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	TAS
GO:0007283	spermatogenesis	IEA
GO:0008630	intrinsic apoptotic signaling pathway in response to DNA damage	IMP
GO:0010628	positive regulation of gene expression	IDA
GO:0016032	viral process	IEA
GO:0030900	forebrain development	IEA
GO:0043065	positive regulation of apoptotic process	IDA
GO:0043276	anoikis	IEA
GO:0043392	negative regulation of DNA binding	IDA
GO:0045599	negative regulation of fat cell differentiation	ISS
GO:0045892	negative regulation of transcription, DNA-templated	IDA
GO:0045892	negative regulation of transcription, DNA-templated	IMP
GO:0045893	positive regulation of transcription, DNA-templated	IMP
GO:0045893	positive regulation of transcription, DNA-templated	IDA
GO:0045944	positive regulation of transcription by RNA polymerase II	IMP
GO:0045944	positive regulation of transcription by RNA polymerase II	IBA
GO:0048146	positive regulation of fibroblast proliferation	IMP
GO:0048255	mRNA stabilization	IDA
GO:0051726	regulation of cell cycle	IBA
GO:0060252	positive regulation of glial cell proliferation	IEA
GO:0070317	negative regulation of G0 to G1 transition	TAS
GO:0070345	negative regulation of fat cell proliferation	ISS
GO:0071398	cellular response to fatty acid	IEA
GO:0071456	cellular response to hypoxia	IEA
GO:0071466	cellular response to xenobiotic stimulus	IEA
GO:0071930	negative regulation of transcription involved in G1/S transition of mitotic cell cycle	IMP
GO:0072332	intrinsic apoptotic signaling pathway by p53 class mediator	IEA
GO:1900740	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	TAS
GO:1990086	lens fiber cell apoptotic process	IEA
GO:1990090	cellular response to nerve growth factor stimulus	IEA
GO:2000045	regulation of G1/S transition of mitotic cell cycle	IMP

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0000790	nuclear chromatin	ISA
GO:0000790	nuclear chromatin	IDA
GO:0005634	nucleus	IDA
GO:0005634	nucleus	IBA
GO:0005654	nucleoplasm	IDA
GO:0005654	nucleoplasm	TAS
GO:0005739	mitochondrion	IEA
GO:0005813	centrosome	IDA
GO:0032991	protein-containing complex	IDA
GO:0035189	Rb-E2F complex	IDA
GO:0090575	RNA polymerase II transcription factor complex	IBA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109581	Apoptosis	TAS
R-HSA-109606	Intrinsic Pathway for Apoptosis	TAS
R-HSA-111448	Activation of NOXA and translocation to mitochondria	TAS
R-HSA-113501	Inhibition of replication initiation of damaged DNA by RB1/E2F1	IEA
R-HSA-113510	E2F mediated regulation of DNA replication	IEA
R-HSA-114452	Activation of BH3-only proteins	TAS
R-HSA-1266738	Developmental Biology	IEA
R-HSA-1266738	Developmental Biology	TAS
R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	TAS
R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	IEA
R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	IEA
R-HSA-139915	Activation of PUMA and translocation to mitochondria	TAS
R-HSA-1538133	G0 and Early G1	TAS
R-HSA-1538133	G0 and Early G1	IEA
R-HSA-157118	Signaling by NOTCH	IEA
R-HSA-157118	Signaling by NOTCH	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-1640170	Cell Cycle	TAS
R-HSA-1640170	Cell Cycle	IEA
R-HSA-1912408	Pre-NOTCH Transcription and Translation	IEA
R-HSA-1912408	Pre-NOTCH Transcription and Translation	TAS
R-HSA-1912422	Pre-NOTCH Expression and Processing	IEA
R-HSA-1912422	Pre-NOTCH Expression and Processing	TAS
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-2262752	Cellular responses to stress	TAS
R-HSA-2559580	Oxidative Stress Induced Senescence	TAS
R-HSA-2559583	Cellular Senescence	TAS
R-HSA-2559585	Oncogene Induced Senescence	TAS
R-HSA-3700989	Transcriptional Regulation by TP53	TAS
R-HSA-453274	Mitotic G2-G2/M phases	TAS
R-HSA-453279	Mitotic G1 phase and G1/S transition	TAS
R-HSA-453279	Mitotic G1 phase and G1/S transition	IEA
R-HSA-5357801	Programmed Cell Death	TAS
R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	TAS
R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	TAS
R-HSA-68689	CDC6 association with the ORC:origin complex	TAS
R-HSA-68867	Assembly of the pre-replicative complex	TAS
R-HSA-68911	G2 Phase	TAS
R-HSA-69002	DNA Replication Pre-Initiation	TAS
R-HSA-69202	Cyclin E associated events during G1/S transition	TAS
R-HSA-69205	G1/S-Specific Transcription	TAS
R-HSA-69205	G1/S-Specific Transcription	IEA
R-HSA-69206	G1/S Transition	TAS
R-HSA-69206	G1/S Transition	IEA
R-HSA-69231	Cyclin D associated events in G1	TAS
R-HSA-69236	G1 Phase	TAS
R-HSA-69242	S Phase	TAS
R-HSA-69278	Cell Cycle, Mitotic	TAS
R-HSA-69278	Cell Cycle, Mitotic	IEA
R-HSA-69306	DNA Replication	TAS
R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	TAS
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8953750	Transcriptional Regulation by E2F6	TAS
R-HSA-8953897	Cellular responses to external stimuli	TAS
R-HSA-9616222	Transcriptional regulation of granulopoiesis	IEA
R-HSA-9616222	Transcriptional regulation of granulopoiesis	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C015699	1,2-benzisothiazoline-3-one	1,2-benzisothiazoline-3-one inhibits the reaction [Estradiol results in increased expression of E2F1 mRNA]	14702633
C015699	1,2-benzisothiazoline-3-one	1,2-benzisothiazoline-3-one inhibits the reaction [Estradiol results in increased expression of E2F1 protein]	14702633
C044985	1',2'-dihydrorotenone	1',2'-dihydrorotenone results in decreased expression of E2F1 protein	24615755
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of E2F1 mRNA	23626729
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [E2F1 protein binds to FOXM1 promoter]	26171734
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [E2F1 protein binds to MYC promoter]	26171734
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of E2F1 mRNA	22698814; 23684557; 26171734;
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of E2F1 protein	12807759; 15382178; 23684557; 26171734;
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	Androstanols inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [E2F1 protein binds to FOXM1 promoter]]	26171734
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	Androstanols inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [E2F1 protein binds to MYC promoter]]	26171734
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	NR1I3 protein promotes the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of E2F1 mRNA]	22698814
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased expression of E2F1 mRNA	30723492
C511295	2,2',4,4'-tetrabromodiphenyl ether	2,2',4,4'-tetrabromodiphenyl ether results in increased expression of E2F1 mRNA	26988655; 30796839;
C511295	2,2',4,4'-tetrabromodiphenyl ether	2,2',4,4'-tetrabromodiphenyl ether results in increased expression of E2F1 protein	26988655
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vanadates results in increased expression of E2F1 protein]	14971663
C076996	27-hydroxycholesterol	27-hydroxycholesterol results in increased expression of E2F1 mRNA	17872378
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in decreased expression of E2F1 protein	15158336
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of E2F1 mRNA	19167416; 22213190;
C497101	2-hydroxy-9-cis-octadecenoic acid	2-hydroxy-9-cis-octadecenoic acid results in decreased expression of E2F1 mRNA	16027227
C497101	2-hydroxy-9-cis-octadecenoic acid	2-hydroxy-9-cis-octadecenoic acid results in decreased expression of E2F1 protein	16027227
C025160	3-aminobenzamide	3-aminobenzamide promotes the reaction [RB1 protein binds to E2F1 protein]	15670817
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of E2F1 mRNA	12419474
C002202	4-oxoretinoic acid	4-oxoretinoic acid results in decreased expression of E2F1 mRNA	15982314
C510786	5-nitroso-8-quinolinol	5-nitroso-8-quinolinol results in decreased expression of E2F1 protein	16497787
C510786	5-nitroso-8-quinolinol	Acetylcysteine inhibits the reaction [5-nitroso-8-quinolinol results in decreased expression of E2F1 protein]	16497787
C580598	5-OH-BDE-47	5-OH-BDE-47 results in increased expression of E2F1 mRNA	26988655
C580599	6-OH-BDE-47	6-OH-BDE-47 results in decreased expression of E2F1 protein	26988655
C580599	6-OH-BDE-47	6-OH-BDE-47 results in increased expression of E2F1 mRNA	26988655
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of E2F1 mRNA	19150397
C553817	7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one	7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one results in decreased expression of E2F1 protein	19936915
C054852	7-hydroxystaurosporine	7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]	22403396
C496492	abrine	abrine results in decreased expression of E2F1 mRNA	31054353
D000082	Acetaminophen	Acetaminophen results in increased expression of E2F1 mRNA	22230336; 25704631;
D000111	Acetylcysteine	Acetylcysteine inhibits the reaction [5-nitroso-8-quinolinol results in decreased expression of E2F1 protein]	16497787
C058956	acteoside	[acteoside results in decreased phosphorylation of RB1 protein] promotes the reaction [RB1 protein binds to E2F1 protein]	17634406
D000225	Adenine	Adenine results in decreased expression of E2F1 mRNA	24211769
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of E2F1 mRNA	15120964
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of E2F1 mRNA	23630614; 25378103;
C000593263	afuresertib	afuresertib results in decreased expression of E2F1 mRNA	28960945
C077990	alvocidib	alvocidib results in decreased expression of E2F1 mRNA	21239698
C077990	alvocidib	alvocidib results in increased expression of E2F1 protein	12533675
C077990	alvocidib	E2F1 results in increased susceptibility to alvocidib	12533675
C557933	AMG 837	AMG 837 results in decreased expression of E2F1 mRNA	30243991
D000643	Ammonium Chloride	Ammonium Chloride results in increased expression of E2F1 protein	16483693
D000655	Amodiaquine	Amodiaquine affects the expression of E2F1 mRNA	24113242
D000655	Amodiaquine	Amodiaquine affects the expression of E2F1 protein	24113242
D000661	Amphetamine	Amphetamine results in decreased expression of E2F1 mRNA	30779732
C059765	amphotericin B, deoxycholate drug combination	amphotericin B, deoxycholate drug combination results in increased expression of E2F1 mRNA	22863853
D000732	Androstanols	Androstanols inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [E2F1 protein binds to FOXM1 promoter]]	26171734
D000732	Androstanols	Androstanols inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene promotes the reaction [E2F1 protein binds to MYC promoter]]	26171734
D000952	Antigens, Polyomavirus Transforming	Antigens, Polyomavirus Transforming results in increased expression of E2F1 mRNA	26680231
C483690	apo-14'-carotenoic acid	apo-14'-carotenoic acid results in decreased expression of E2F1 protein	12042460
D001151	Arsenic	Arsenic results in decreased expression of E2F1 mRNA	19945496
D001151	Arsenic	Arsenic results in increased expression of E2F1 protein	23174854
D001151	Arsenic	E2F1 protein affects the reaction [Arsenic results in increased expression of AURKA protein]	23174854
D000077237	Arsenic Trioxide	Arsenic Trioxide affects the methylation of E2F1 promoter	26046465
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of E2F1 protein	24691991; 25174355; 25335113;
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of E2F1 mRNA	20016248
D017636	Asbestos, Amphibole	Asbestos, Amphibole results in decreased expression of E2F1 protein	20855422
C010302	aspidin BB	aspidin BB results in increased expression of E2F1 protein	23628508
D001241	Aspirin	Aspirin inhibits the reaction [E2F1 protein binds to BIRC5 promoter]	17848598
D001241	Aspirin	Aspirin results in decreased expression of E2F1 mRNA	20457246
D001241	Aspirin	[Troglitazone co-treated with Aspirin] results in decreased expression of E2F1 protein	19908241
D001280	Atrazine	Atrazine results in decreased expression of E2F1 mRNA	22378314
C105832	aurapten	aurapten affects the expression of E2F1 mRNA	23320178
D001374	Azacitidine	E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]	19451745
D001374	Azacitidine	E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]	19451745
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the activity of E2F1 protein	20624995
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of E2F1 mRNA	20064835; 21802500;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of E2F1 protein	21802500
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of E2F1 protein	16406622
D001564	Benzo(a)pyrene	CCND1 protein promotes the reaction [Benzo(a)pyrene results in increased expression of E2F1 protein]	16406622
D001564	Benzo(a)pyrene	CDK4 protein promotes the reaction [Benzo(a)pyrene results in increased expression of E2F1 protein]	16406622
D001564	Benzo(a)pyrene	Tretinoin inhibits the reaction [Benzo(a)pyrene results in increased expression of E2F1 protein]	16406622
D053119	Benzophenanthridines	Benzophenanthridines analog results in decreased expression of E2F1 mRNA	23117580
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dronabinol results in decreased expression of E2F1 protein]	17934890
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of E2F1 mRNA	30684532
C006780	bisphenol A	bisphenol A affects the expression of E2F1 mRNA	30903817
C006780	bisphenol A	bisphenol A results in increased expression of E2F1 protein	21277958; 25933419;
C006780	bisphenol A	bisphenol A results in decreased expression of E2F1 mRNA	25181051
D000069286	Bortezomib	[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein	25522274
C038091	butylparaben	butylparaben affects the expression of E2F1 mRNA	24481588
C584509	C646 compound	C646 compound results in decreased expression of E2F1 mRNA	26191083
D002104	Cadmium	Cadmium results in decreased expression of E2F1 mRNA	20839231
C028031	cadmium acetate	cadmium acetate affects the localization of E2F1 protein	20839231
C028031	cadmium acetate	cadmium acetate promotes the reaction [RB1 protein modified form binds to E2F1 protein]	20839231
C028031	cadmium acetate	cadmium acetate results in decreased activity of E2F1 protein	20839231
C028031	cadmium acetate	cadmium acetate results in decreased expression of E2F1 mRNA	18155341; 20839231;
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of E2F1 mRNA	27510461
D019256	Cadmium Chloride	Cadmium Chloride inhibits the reaction [SP1 protein binds to SP3 protein binds to KLF4 protein binds to E2F1 protein binds to NECTIN2 promoter]	25046863
D002110	Caffeine	Caffeine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]	22403396
D002117	Calcitriol	Calcitriol promotes the reaction [Testosterone results in decreased expression of E2F1 mRNA]	21592394
D002117	Calcitriol	Calcitriol results in decreased expression of E2F1 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in decreased expression of E2F1 mRNA	21592394
D002117	Calcitriol	Testosterone promotes the reaction [Calcitriol results in decreased expression of E2F1 mRNA]	21592394
D002166	Camptothecin	7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]	22403396
D002166	Camptothecin	Caffeine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]	22403396
D002166	Camptothecin	Camptothecin results in increased expression of E2F1 mRNA	22403396
D002166	Camptothecin	E2F1 protein promotes the reaction [Camptothecin results in increased expression of RRM2 protein]	22403396
D002211	Capsaicin	Capsaicin results in increased expression of E2F1 mRNA	19502594
D002220	Carbamazepine	Carbamazepine affects the expression of E2F1 mRNA	24752500
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of E2F1 mRNA	17484886
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of E2F1 protein	19887370
C038590	cardanol	cardanol results in increased expression of E2F1 mRNA	26694491
D002330	Carmustine	Carmustine results in increased expression of E2F1 protein	18632648
C099555	CD 437	CD 437 results in increased expression of E2F1 protein	10766194
D002746	Chlorpromazine	Chlorpromazine analog results in decreased expression of E2F1 mRNA	15924885
D002794	Choline	Choline results in increased expression of E2F1 mRNA	16014740
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of E2F1 gene	20938992
D000077407	Cilostazol	Cilostazol results in decreased expression of E2F1 protein	15723965
D002945	Cisplatin	Cisplatin results in decreased expression of E2F1 mRNA	24211769
D002945	Cisplatin	Cisplatin results in increased acetylation of E2F1 protein	21157427
D002945	Cisplatin	Cisplatin results in increased expression of E2F1 mRNA	21603599
D002953	Citrinin	Citrinin results in increased expression of E2F1 mRNA	23856526
D003035	Cobalt	[Nickel co-treated with Cobalt co-treated with Tungsten] results in decreased expression of E2F1 mRNA	22198552
D003078	Colchicine	Colchicine results in decreased expression of E2F1 mRNA	24211769
D003300	Copper	[NSC 689534 binds to Copper] which results in decreased expression of E2F1 mRNA	20971185
D003300	Copper	Copper deficiency results in increased expression of E2F1 mRNA	17418555
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of E2F1 mRNA	19549813
D003375	Coumestrol	[Coumestrol co-treated with Resveratrol] results in increased expression of E2F1 mRNA	19167446
D003474	Curcumin	Curcumin results in decreased expression of E2F1 mRNA	18299980
D003634	DDT	DDT results in increased expression of E2F1 mRNA	23684557
D003634	DDT	DDT results in increased expression of E2F1 protein	23684557
D003634	DDT	Fulvestrant inhibits the reaction [DDT results in increased expression of E2F1 mRNA]	23684557
D000077209	Decitabine	Decitabine results in increased expression of E2F1 mRNA	27915011
C576677	demycarosyl-3D-digitoxosylmithramycin SK	demycarosyl-3D-digitoxosylmithramycin SK results in decreased expression of E2F1 mRNA	24907531
C100805	DIBA-1	DIBA-1 inhibits the reaction [Estradiol results in increased expression of E2F1 mRNA]	14702633
C100805	DIBA-1	DIBA-1 inhibits the reaction [Estradiol results in increased expression of E2F1 protein]	14702633
C100805	DIBA-1	DIBA-1 results in decreased expression of E2F1 mRNA	14702633
C041517	dibenzo(a,l)pyrene	dibenzo(a,l)pyrene results in increased expression of E2F1 mRNA	16269432
D004008	Diclofenac	Diclofenac affects the expression of E2F1 mRNA	24752500
D004026	Dieldrin	Dieldrin affects the expression of E2F1 mRNA	22546817
D004026	Dieldrin	Dieldrin results in increased expression of E2F1 mRNA	23153324
C020283	diethanolamine	diethanolamine results in increased expression of E2F1 mRNA	16014740
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Piperonyl Butoxide] results in increased expression of E2F1 mRNA	20101389
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of E2F1 mRNA	17854601
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of E2F1 protein	17854601; 19887370;
D004052	Diethylnitrosamine	RB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of E2F1 mRNA]	17854601
D004052	Diethylnitrosamine	RB1 protein inhibits the reaction [Diethylnitrosamine results in increased expression of E2F1 protein]	17854601; 19887370;
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of E2F1 mRNA	15647840
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of E2F1 protein	15647840
C547156	dimethylthioarsinic acid	dimethylthioarsinic acid results in decreased expression of E2F1 mRNA	19945496
D004137	Dinitrochlorobenzene	Dinitrochlorobenzene affects the expression of E2F1 mRNA	22302311
D004317	Doxorubicin	Doxorubicin affects the expression of E2F1 protein	25124555
D004317	Doxorubicin	Doxorubicin inhibits the reaction [[RBBP8 protein binds to BRCA1 protein binds to E2F1 protein] which results in increased expression of ATM mRNA]	22832221
D004317	Doxorubicin	Doxorubicin promotes the reaction [E2F1 protein binds to CCNE1 promoter]	25124555
D004317	Doxorubicin	Doxorubicin promotes the reaction [E2F1 protein binds to TP73 promoter]	25124555
D004317	Doxorubicin	Doxorubicin promotes the reaction [E2F1 protein results in decreased expression of ATM mRNA]	22832221
D004317	Doxorubicin	Doxorubicin results in decreased expression of E2F1 mRNA	24816189
D004317	Doxorubicin	Doxorubicin results in decreased expression of E2F1 protein	24816189
D004317	Doxorubicin	Doxorubicin results in increased expression of E2F1 protein	22751436
D004317	Doxorubicin	E2F1 protein affects the susceptibility to Doxorubicin	25124555
D004317	Doxorubicin	E2F1 protein promotes the reaction [Doxorubicin results in increased expression of CCNE1 protein]	25124555
D004317	Doxorubicin	E2F1 protein promotes the reaction [Doxorubicin results in increased expression of TP73 protein]	25124555
D004317	Doxorubicin	palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]	22751436
D004317	Doxorubicin	RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]	22751436
D004317	Doxorubicin	SETD7 protein promotes the reaction [Doxorubicin affects the expression of E2F1 protein]	25124555
D004317	Doxorubicin	SETD7 protein promotes the reaction [Doxorubicin promotes the reaction [E2F1 protein binds to CCNE1 promoter]]	25124555
D004317	Doxorubicin	SETD7 protein promotes the reaction [Doxorubicin promotes the reaction [E2F1 protein binds to TP73 promoter]]	25124555
D013759	Dronabinol	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Dronabinol results in decreased expression of E2F1 protein]	17934890
D013759	Dronabinol	Dronabinol results in decreased expression of E2F1 mRNA	17934890
D013759	Dronabinol	Dronabinol results in decreased expression of E2F1 protein	17934890
C509867	E804 bisindole	E804 bisindole results in decreased expression of E2F1 mRNA	23107598
C509867	E804 bisindole	Lipopolysaccharides promotes the reaction [E804 bisindole results in decreased expression of E2F1 mRNA]	23107598
D004726	Endosulfan	Endosulfan results in decreased expression of E2F1 mRNA	30090376
D004958	Estradiol	1,2-benzisothiazoline-3-one inhibits the reaction [Estradiol results in increased expression of E2F1 mRNA]	14702633
D004958	Estradiol	1,2-benzisothiazoline-3-one inhibits the reaction [Estradiol results in increased expression of E2F1 protein]	14702633
D004958	Estradiol	DIBA-1 inhibits the reaction [Estradiol results in increased expression of E2F1 mRNA]	14702633
D004958	Estradiol	DIBA-1 inhibits the reaction [Estradiol results in increased expression of E2F1 protein]	14702633
D004958	Estradiol	ESR1 protein affects the reaction [Estradiol results in increased expression of E2F1 mRNA]	28880708
D004958	Estradiol	Estradiol affects the expression of E2F1 protein	28880708
D004958	Estradiol	Estradiol inhibits the reaction [E2F1 protein binds to RB1 protein modified form binds to E2F1 promoter]	28880708; 28880708;
D004958	Estradiol	Estradiol results in increased activity of E2F1 protein	27592001
D004958	Estradiol	Estradiol results in increased expression of E2F1 mRNA	14702633; 17872378; 23094148; 24481588; 28880708;
D004958	Estradiol	Estradiol results in increased expression of E2F1 protein	14702633
D004958	Estradiol	sodium arsenite affects the reaction [Estradiol affects the expression of E2F1 protein]	28880708
D004958	Estradiol	sodium arsenite inhibits the reaction [Estradiol inhibits the reaction [E2F1 protein binds to RB1 protein modified form binds to E2F1 promoter]]	28880708; 28880708;
D004958	Estradiol	sodium arsenite inhibits the reaction [Estradiol results in increased expression of E2F1 mRNA]	28880708
D004958	Estradiol	ESR1 protein promotes the reaction [Estradiol results in increased expression of E2F1 mRNA]	25210133
D004958	Estradiol	Estradiol affects the expression of E2F1 mRNA	15598610
D004958	Estradiol	Estradiol results in increased expression of E2F1 mRNA	23684557; 25210133;
D004958	Estradiol	Estradiol results in increased expression of E2F1 protein	23684557
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of E2F1 mRNA	14976129; 17942748;
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of E2F1 mRNA	17942748
C002994	ethylene dimethanesulfonate	ethylene dimethanesulfonate results in decreased expression of E2F1 mRNA	22711419
D005047	Etoposide	E2F1 protein affects the reaction [Etoposide results in increased expression of HIC1 mRNA]	19491197
D005047	Etoposide	Etoposide promotes the reaction [E2F1 protein binds to HIC1 promoter]	19491197
D005054	Eugenol	Eugenol results in decreased expression of E2F1 mRNA	15574415
D005054	Eugenol	Eugenol results in decreased expression of E2F1 protein	15574415
D005054	Eugenol	Eugenol results in decreased activity of E2F1 protein	15574415
C063007	exoenzyme C3, Clostridium botulinum	exoenzyme C3, Clostridium botulinum results in decreased expression of E2F1 mRNA	27351882
C093323	farnesylthiosalicylic acid	farnesylthiosalicylic acid results in decreased expression of E2F1 protein	16780807
D017313	Fenretinide	Fenretinide results in decreased expression of E2F1 mRNA	28973697
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of E2F1 gene	20938992
D000077267	Fulvestrant	Fulvestrant results in decreased expression of E2F1 mRNA	20215421
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [DDT results in increased expression of E2F1 mRNA]	23684557
C039281	furan	furan results in increased expression of E2F1 mRNA	20562052; 22079235;
D000077156	Gefitinib	Gefitinib results in decreased expression of E2F1 mRNA	17094457
D000077156	Gefitinib	Gefitinib results in decreased expression of E2F1 protein	17094457; 18347146;
C007836	geraniol	geraniol results in decreased expression of E2F1 mRNA	27683099
C000593030	GSK-J4	GSK-J4 results in decreased expression of E2F1 mRNA	29301935
C479979	GW0742	[GW0742 binds to and results in increased activity of PPARD protein] which results in decreased expression of E2F1 protein	22473992
D006247	Harmine	Harmine results in increased expression of E2F1 mRNA	25751815
D006247	Harmine	Harmine results in increased expression of E2F1 protein	25751815
D006493	Heparin	Heparin analog results in decreased expression of E2F1 protein	20201787
C080043	hexyl cinnamic aldehyde	hexyl cinnamic aldehyde affects the expression of E2F1 mRNA	22302311
C403899	HS 1030	HS 1030 promotes the reaction [RB1 protein binds to E2F1 protein]	15202011
C403900	HS 1183	HS 1183 promotes the reaction [RB1 protein binds to E2F1 protein]	15202011
C503536	HS-1199	HS-1199 promotes the reaction [RB1 protein binds to E2F1 protein]	15202011
C479128	HS 1200	HS 1200 promotes the reaction [RB1 protein binds to E2F1 protein]	15202011
D006918	Hydroxyurea	Hydroxyurea results in decreased expression of E2F1 mRNA	24211769
C027185	indirubin	indirubin results in decreased expression of E2F1 mRNA	15056799
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of E2F1 mRNA	25613284
D007501	Iron	[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of E2F1 mRNA	22198552
C544151	jinfukang	jinfukang results in increased expression of E2F1 mRNA	27392435
C561695	(+)-JQ1 compound	[(+)-JQ1 compound co-treated with Vemurafenib] results in decreased expression of E2F1 mRNA	27169980
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased activity of E2F1 protein	24796395
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of E2F1 mRNA	25961927
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of E2F1 protein	25174395
C017461	lead nitrate	E2F1 protein inhibits the reaction [lead nitrate results in decreased expression of DNMT3A mRNA]	24639330
C017461	lead nitrate	E2F1 protein inhibits the reaction [lead nitrate results in increased expression of PTGS2 mRNA]	24639330
C017461	lead nitrate	lead nitrate inhibits the reaction [E2F1 protein results in decreased expression of PTGS2 mRNA]	24639330
C038753	leptomycin B	leptomycin B results in decreased expression of E2F1 mRNA	20803015
D008012	Lidocaine	Lidocaine affects the expression of E2F1 mRNA	18931217
D008070	Lipopolysaccharides	E2F1 protein promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]	21131441
D008070	Lipopolysaccharides	E2F1 protein promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]	21131441
D008070	Lipopolysaccharides	E2F1 protein results in increased susceptibility to Lipopolysaccharides	21131441
D008070	Lipopolysaccharides	Lipopolysaccharides promotes the reaction [E804 bisindole results in decreased expression of E2F1 mRNA]	23107598
D058185	Magnetite Nanoparticles	Magnetite Nanoparticles results in increased expression of E2F1 mRNA	25532727
D008344	Maneb	[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA	23963992
D008344	Maneb	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]	23963992
D008550	Melatonin	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]	23963992
D008610	Menthol	Menthol results in increased expression of E2F1 mRNA	26760959
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of E2F1 gene	20938992
D008727	Methotrexate	Methotrexate inhibits the reaction [RB1 protein binds to E2F1 protein]	22484375
D008727	Methotrexate	Methotrexate promotes the reaction [E2F1 protein binds to CHEK1 promoter]	22484375
D008727	Methotrexate	Methotrexate promotes the reaction [E2F1 protein binds to KAT2B protein]	22484375
D008727	Methotrexate	Methotrexate results in decreased methylation of and results in increased acetylation of E2F1 protein	22484375
D008727	Methotrexate	Methotrexate promotes the reaction [E2F1 protein binds to DHFR promoter]	22484375
C008493	methylselenic acid	methylselenic acid affects the expression of E2F1 mRNA	14617803
C008493	methylselenic acid	methylselenic acid promotes the reaction [E2F1 protein binds to RB1 protein]	17847021
C008493	methylselenic acid	methylselenic acid results in decreased expression of E2F1 mRNA	11830524
C008493	methylselenic acid	methylselenic acid results in decreased expression of E2F1 protein	17847021
D015735	Mifepristone	Mifepristone results in decreased expression of E2F1 protein	17545545
D016685	Mitomycin	Mitomycin results in decreased expression of E2F1 mRNA	24211769
C060893	MK-886	MK-886 inhibits the reaction [Nicotine results in increased expression of E2F1 protein]	20061081
D016686	Monocrotaline	[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA	21224054
C406082	monomethylarsonous acid	monomethylarsonous acid results in decreased expression of E2F1 mRNA	19945496
C437683	motexafin gadolinium	motexafin gadolinium results in increased expression of E2F1 mRNA	16357179
C437683	motexafin gadolinium	[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F1 mRNA	16357179
D009151	Mustard Gas	Mustard Gas results in increased expression of E2F1 mRNA	18955075
D037742	Nanotubes, Carbon	Nanotubes, Carbon affects the expression of E2F1 mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog affects the expression of E2F1 mRNA	25554681
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in decreased expression of E2F1 mRNA	25620056
D009532	Nickel	[Nickel co-treated with Cobalt co-treated with Tungsten] results in decreased expression of E2F1 mRNA	22198552
D009532	Nickel	[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of E2F1 mRNA	22198552
C022838	nickel chloride	HIF1A affects the reaction [nickel chloride results in increased expression of E2F1 mRNA]	12729255
C022838	nickel chloride	nickel chloride results in increased expression of E2F1 mRNA	12729255
C022838	nickel chloride	nickel chloride affects the expression of E2F1 mRNA	22546817
D009534	Niclosamide	Niclosamide results in decreased expression of E2F1 mRNA	29843133
D009538	Nicotine	MK-886 inhibits the reaction [Nicotine results in increased expression of E2F1 protein]	20061081
D009538	Nicotine	Nicotine promotes the reaction [E2F1 protein binds to BIRC5 promoter]	16601104
D009538	Nicotine	Nicotine promotes the reaction [E2F1 protein binds to CDC25A promoter]	16862215
D009538	Nicotine	Nicotine promotes the reaction [E2F1 protein binds to CDC6 promoter]	16862215
D009538	Nicotine	Nicotine results in increased expression of E2F1 protein	20061081
C558013	NSC 689534	[NSC 689534 binds to Copper] which results in decreased expression of E2F1 mRNA	20971185
C025589	ochratoxin A	ochratoxin A results in increased acetylation of E2F1 promoter	29098329
C025589	ochratoxin A	[ochratoxin A results in increased acetylation of E2F1 promoter] which results in increased expression of E2F1 mRNA	29098329; 29098329;
C025589	ochratoxin A	ochratoxin A results in increased expression of E2F1 mRNA	29098329
D019301	Oleic Acid	Oleic Acid results in decreased expression of E2F1 protein	16027227
D009840	Oligomycins	Oligomycins promotes the reaction [RB1 protein binds to E2F1 protein]	15925326
D009764	o-Phthalaldehyde	o-Phthalaldehyde affects the expression of E2F1 mRNA	22302311
D010100	Oxygen	Oxygen deficiency results in decreased expression of E2F1 mRNA	26516004
D017239	Paclitaxel	E2F1 protein results in increased susceptibility to Paclitaxel	16849574
C500026	palbociclib	palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]	22751436
C500026	palbociclib	RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]	22751436
C500026	palbociclib	E2F1 protein affects the susceptibility to palbociclib	23898052
D010269	Paraquat	[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA	23963992
D010269	Paraquat	Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]	23963992
C074968	pentaacetyl geniposide	pentaacetyl geniposide results in decreased phosphorylation of E2F1 protein	15975050
C517827	pentabrominated diphenyl ether 100	pentabrominated diphenyl ether 100 results in increased expression of E2F1 mRNA	30796839
D010416	Pentachlorophenol	Pentachlorophenol results in increased expression of E2F1 protein	19442831
C011272	perfosfamide	perfosfamide results in increased expression of E2F1 mRNA	19429390
D010634	Phenobarbital	Phenobarbital affects the expression of E2F1 mRNA	23091169
D010672	Phenytoin	[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA	21224054
C030090	phosphoramide mustard	phosphoramide mustard results in increased expression of E2F1 mRNA	26708502
D010882	Piperonyl Butoxide	[Diethylnitrosamine co-treated with Piperonyl Butoxide] results in increased expression of E2F1 mRNA	20101389
C006253	pirinixic acid	pirinixic acid results in increased expression of E2F1 mRNA	23811191
D010936	Plant Extracts	Plant Extracts results in decreased expression of E2F1 protein	15327971
D011285	Pregnenolone Carbonitrile	[1,4-bis(2-(3,5-dichloropyridyloxy))benzene co-treated with Pregnenolone Carbonitrile] results in increased expression of E2F1 mRNA	23626729
D011374	Progesterone	Progesterone results in decreased expression of E2F1 mRNA	16966611
C006068	propylparaben	propylparaben results in increased expression of E2F1 mRNA	24481588
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of E2F1 mRNA	25825206
D011441	Propylthiouracil	Propylthiouracil results in increased expression of E2F1 mRNA	24780913
C573121	ProstaCaid	ProstaCaid results in decreased expression of E2F1 mRNA	21468543
C014175	pyrazolo(3,4-d)pyrimidine	pyrazolo(3,4-d)pyrimidine analog affects the expression of E2F1 mRNA	21152443
D011794	Quercetin	Quercetin results in increased expression of E2F1 mRNA	21632981; 27514524;
C037219	quinoline	quinoline analog affects the expression of E2F1 protein	15450938
D000077185	Resveratrol	Resveratrol inhibits the reaction [IL1B protein results in increased activity of E2F1 protein]	19011540
D000077185	Resveratrol	[Coumestrol co-treated with Resveratrol] results in increased expression of E2F1 mRNA	19167446
D012293	Rifampin	[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA	21224054
D019438	Ritonavir	Ritonavir results in decreased expression of E2F1 mRNA	19386116
D019438	Ritonavir	Ritonavir results in decreased expression of E2F1 protein	19386116
D012643	Selenium	Selenium results in increased expression of E2F1 mRNA	19244175
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of E2F1 mRNA	23806026
D012835	Silver Nitrate	Silver Nitrate analog results in increased expression of E2F1 mRNA	22831968
D019821	Simvastatin	Simvastatin results in decreased expression of E2F1 mRNA	17428261
D020123	Sirolimus	[TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 mRNA	12417722
D020123	Sirolimus	[TGFB1 protein co-treated with Sirolimus] results in decreased expression of E2F1 protein	12417722
C009277	sodium arsenate	sodium arsenate results in decreased expression of E2F1 mRNA	24349563
C017947	sodium arsenite	sodium arsenite affects the reaction [Estradiol affects the expression of E2F1 protein]	28880708
C017947	sodium arsenite	sodium arsenite inhibits the reaction [Estradiol inhibits the reaction [E2F1 protein binds to RB1 protein modified form binds to E2F1 promoter]]	28880708; 28880708;
C017947	sodium arsenite	sodium arsenite inhibits the reaction [Estradiol results in increased expression of E2F1 mRNA]	28880708
C017947	sodium arsenite	sodium arsenite results in increased expression of E2F1 mRNA	28595984; 29301061;
C017947	sodium arsenite	sodium arsenite inhibits the reaction [E2F1 protein binds to DLGAP5 promoter]	17998272
C017947	sodium arsenite	sodium arsenite inhibits the reaction [E2F1 protein binds to MELK promoter]	17998272
C017947	sodium arsenite	sodium arsenite inhibits the reaction [PDK4 gene mutant form results in increased expression of E2F1 protein]	28003426
C017947	sodium arsenite	sodium arsenite results in increased expression of E2F1 protein	10764629
D013467	Sulindac	Sulindac results in decreased expression of E2F1 protein	16488075
C557331	TAK-875	TAK-875 results in decreased expression of E2F1 mRNA	30243991
D013629	Tamoxifen	Tamoxifen promotes the reaction [[ESR1 protein binds to SP1 protein] which binds to E2F1 promoter]	20215421
D013629	Tamoxifen	Tamoxifen promotes the reaction [[[ESR1 protein binds to SP1 protein] which binds to E2F1 promoter] which results in increased expression of E2F1 mRNA]	20215421; 20215421;
D013629	Tamoxifen	Tamoxifen results in decreased expression of E2F1 mRNA	15590111
D013629	Tamoxifen	Tamoxifen results in increased expression of E2F1 mRNA	20215421
D013629	Tamoxifen	Tamoxifen results in increased expression of E2F1 protein	20215421
D013629	Tamoxifen	Tamoxifen results in decreased expression of E2F1 protein	17343880
D013629	Tamoxifen	[Tamoxifen results in increased expression of MIR17 mRNA] which results in decreased expression of E2F1 protein	17343880
D013629	Tamoxifen	[Tamoxifen results in increased expression of MIR92A1 mRNA] which results in decreased expression of E2F1 protein	17343880
C030141	taurine-ursodeoxycholate conjugate	taurine-ursodeoxycholate conjugate inhibits the reaction [E2F1 protein results in increased expression of BAX protein]	14514686
C030141	taurine-ursodeoxycholate conjugate	taurine-ursodeoxycholate conjugate inhibits the reaction [E2F1 protein results in increased expression of TP53 protein]	14514686
C030141	taurine-ursodeoxycholate conjugate	taurine-ursodeoxycholate conjugate inhibits the reaction [TGFB1 protein results in increased expression of E2F1 mRNA]	14514686
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid results in decreased expression of E2F1 protein	15255934
C031655	tauroursodeoxycholic acid	tauroursodeoxycholic acid results in increased expression of E2F1 mRNA	15255934
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in decreased expression of E2F1 mRNA	12419474
D013739	Testosterone	Calcitriol promotes the reaction [Testosterone results in decreased expression of E2F1 mRNA]	21592394
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in decreased expression of E2F1 mRNA	21592394
D013739	Testosterone	Testosterone promotes the reaction [Calcitriol results in decreased expression of E2F1 mRNA]	21592394
D013739	Testosterone	Testosterone results in decreased expression of E2F1 mRNA	21592394
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of E2F1 mRNA	15056799; 21802500;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of E2F1 protein	21802500
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of E2F1 mRNA	21570461; 24058054;
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of E2F1 mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of E2F1 mRNA	15667827
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of E2F1 mRNA	25613284
C042172	thallium nitrate	EGF protein affects the reaction [thallium nitrate analog results in increased expression of E2F1 protein]	25534134
C042172	thallium nitrate	EGF protein promotes the reaction [thallium nitrate results in increased expression of E2F1 protein]	25534134
C042172	thallium nitrate	thallium nitrate analog results in increased expression of E2F1 protein	25534134
C042172	thallium nitrate	thallium nitrate results in increased expression of E2F1 protein	25534134
D019284	Thapsigargin	Thapsigargin results in decreased expression of E2F1 mRNA	22378314
D013853	Thioacetamide	Thioacetamide results in increased expression of E2F1 mRNA	16297948
D024505	Tocopherols	Tocopherols results in increased expression of E2F1 protein	15883045
D014051	Toluene 2,4-Diisocyanate	Toluene 2,4-Diisocyanate results in increased expression of E2F1 mRNA	21404309
D014118	Toxins, Biological	Toxins, Biological affects the expression of E2F1 mRNA	19682533
D000077606	Trabectedin	Trabectedin results in increased expression of E2F1 mRNA	15961672
D014212	Tretinoin	Tretinoin inhibits the reaction [Benzo(a)pyrene results in increased expression of E2F1 protein]	16406622
D014212	Tretinoin	Tretinoin metabolite results in decreased expression of E2F1 mRNA	15982314
D014212	Tretinoin	Tretinoin results in decreased expression of E2F1 mRNA	23724009
D014212	Tretinoin	Tretinoin results in decreased expression of E2F1 protein	12042460
D014212	Tretinoin	Tretinoin results in increased expression of E2F1 mRNA	17218384
C015559	trimellitic anhydride	trimellitic anhydride affects the expression of E2F1 mRNA	22302311
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of E2F1 mRNA	19042947
C001899	triptolide	triptolide results in increased expression of E2F1 mRNA	23639586
C016805	tris(1,3-dichloro-2-propyl)phosphate	tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of E2F1 mRNA	26179874
D000077288	Troglitazone	[Troglitazone co-treated with Aspirin] results in decreased expression of E2F1 protein	19908241
D000077288	Troglitazone	Troglitazone results in decreased expression of E2F1 mRNA	19140230; 19631733;
D014414	Tungsten	[Nickel co-treated with Cobalt co-treated with Tungsten] results in decreased expression of E2F1 mRNA	22198552
D014414	Tungsten	[Nickel co-treated with Iron co-treated with Tungsten] results in decreased expression of E2F1 mRNA	22198552
D014415	Tunicamycin	Tunicamycin results in decreased expression of E2F1 mRNA	22378314
C000602704	UF010 compound	UF010 compound results in decreased activity of E2F1 protein	25699604
D014520	Urethane	Urethane results in decreased expression of E2F1 mRNA	28818685
D014520	Urethane	Urethane results in increased expression of E2F1 mRNA	12117781
D014580	Ursodeoxycholic Acid	NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]	15222754
D014580	Ursodeoxycholic Acid	NR3C1 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased expression of E2F1 protein]	15222754
D014580	Ursodeoxycholic Acid	NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]]	15222754
D014580	Ursodeoxycholic Acid	NR3C2 mutant form inhibits the reaction [Ursodeoxycholic Acid results in decreased expression of E2F1 protein]	15222754
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid inhibits the reaction [E2F1 protein results in increased expression of BAX protein]	14514686
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid inhibits the reaction [E2F1 protein results in increased expression of TP53 protein]	14514686
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 mRNA]	14514686
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid inhibits the reaction [TGFB1 protein results in increased expression of E2F1 protein]	15222754
D014580	Ursodeoxycholic Acid	Ursodeoxycholic Acid results in decreased expression of E2F1 protein	15222754
D014635	Valproic Acid	Valproic Acid affects the expression of E2F1 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of E2F1 mRNA	20585447
D014635	Valproic Acid	Valproic Acid results in increased methylation of E2F1 gene	29154799
D014638	Vanadates	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vanadates results in increased expression of E2F1 protein]	14971663
D014638	Vanadates	Vanadates results in increased expression of E2F1 protein	14971663
D014638	Vanadates	Wortmannin inhibits the reaction [Vanadates results in increased expression of E2F1 protein]	14971663
D000077484	Vemurafenib	[(+)-JQ1 compound co-treated with Vemurafenib] results in decreased expression of E2F1 mRNA	27169980
D014747	Vinblastine	E2F1 protein results in increased susceptibility to Vinblastine	16849574
C017963	vinyl carbamate	vinyl carbamate results in decreased expression of E2F1 mRNA	17849452
D024483	Vitamin K 3	Vitamin K 3 affects the expression of E2F1 mRNA	20044591
D000077191	Wortmannin	Wortmannin inhibits the reaction [Vanadates results in increased expression of E2F1 protein]	14971663
D019345	Zinc Acetate	[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F1 mRNA	16357179
D019345	Zinc Acetate	Zinc Acetate results in increased expression of E2F1 mRNA	16357179

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0007	Acetylation
KW-0010	Activator
KW-0053	Apoptosis
KW-0131	Cell cycle
KW-0238	DNA-binding
KW-0945	Host-virus interaction
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0804	Transcription
KW-0805	Transcription regulation

Interpro

InterPro ID	InterPro Term
IPR015633	E2F
IPR037241	E2F-DP_heterodim
IPR032198	E2F_CC-MB
IPR003316	E2F_WHTH_DNA-bd_dom
IPR036388	WH-like_DNA-bd_sf
IPR036390	WH_DNA-bd_sf

PROSITE

PROSITE ID	PROSITE Term

Pfam

Pfam ID	Pfam Term
PF16421	E2F_CC-MB
PF02319	E2F_TDP

Gene: E2F1

Basic information

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction